Blog
CBD for Inflammation: What the Trials Actually Measured
CBD for Inflammation: What the Trials Actually Measured
CBD for Inflammation: What the Trials Actually Measured
When a research team publishes a trial, they get one line to name what they found, and they take that line seriously. In 2021, a group of Israeli gastroenterologists chose this one: Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease.
Read it twice. The patients got better. The disease did not.
That gap is the entire story of CBD for inflammation, and almost nothing written about the subject admits it exists. The marketing skips it. So do most of the articles answering the question you typed to get here. It deserves better, because the gap is not a technicality. For anyone living with an inflammatory disease, it is the difference between feeling well and being well, and those two things can come apart quietly.
Inflammation Is Not a Feeling
Start here, because the confusion begins with the word.
Inflammation is your immune system responding to something. Cut your finger and the area goes red, hot, and swollen for a few days while the repair crew works. That is acute inflammation, and it is the system operating correctly.
Chronic inflammation is the same machinery stuck in the on position. In rheumatoid arthritis, immune cells attack the lining of your own joints. In Crohn’s disease and ulcerative colitis, they attack the lining of your intestine. The process runs for years, and it damages the tissue it runs through. According to a 2026 analysis of national survey data by researchers at the CDC and the National Institutes of Health, an estimated 24.8 million American adults with arthritis reported an activity limitation in 2023, roughly half of everyone the survey counted as having the disease.
You cannot feel inflammation. You feel what it does to you: pain, stiffness, swelling, urgency, exhaustion. Physicians measure the inflammation itself with separate tools: C-reactive protein in blood, calprotectin in stool, and, when it counts, a camera or an imaging scan showing what the tissue looks like.
Two sets of measurements. Symptoms on one side, inflammation on the other. Most of the time they move together, which is why we treat them as the same thing in conversation.
But when a treatment moves one of those two sets of measurements and leaves the other exactly where it was, the word “works” stops meaning anything useful.
Why CBD Should Work, On Paper
The biology here is real, and it is worth understanding before we get to what happened in humans.
Your body runs an endocannabinoid system, a network of receptors and signalling molecules for mood, sleep, appetite, pain, and immune activity. Two receptor types do most of the work. CB1 sits mainly in the nervous system. CB2 concentrates in immune cells.
That second detail is why researchers got interested. If your immune cells carry receptors for cannabis-like compounds, then cannabis-like compounds ought to be able to talk to your immune cells. In the laboratory, they do exactly that. CBD suppresses the release of inflammatory signalling proteins, slows the multiplication of immune cells, and calms the chemical burst white blood cells produce when they attack.
None of that is fringe science. It is well replicated and mechanically sensible. The National Center for Complementary and Integrative Health tracks this literature and reaches the same split verdict: interesting mechanisms, thin human evidence.
It is also every bit of it a reason to run a trial, not a reason to believe one has already succeeded.
In Animals, It Works Genuinely Well
Although the human results ahead are the reason this article exists, the animal work came first and it is where the enthusiasm comes from. It earns some.
In 2000, a team at the Kennedy Institute of Rheumatology in London gave CBD to mice with collagen-induced arthritis, a standard laboratory model of the disease, by injection in some experiments and by mouth in others. They started treatment after symptoms had already appeared. Published in the Proceedings of the National Academy of Sciences, the result was striking: CBD blocked the progression of arthritis in both the acute and the chronic relapsing versions of the model, and it worked about equally well by either route. The joints were protected against severe damage. Immune cells taken from treated mice produced less inflammatory signaling.
One detail from that paper deserves more attention than it gets. If the dose-response curve had run the way most people assume drugs work, with more producing more, these results would have pointed straight at a clinical target. It did not. The curve was bell-shaped. There was an optimal amount, and going above it made the effect weaker, not stronger. More was not better in mice, and that pattern shows up repeatedly across cannabinoid research.
Because a compound can look impressive in an animal for reasons unrelated to the animal’s experience, the second study worth knowing measured the tissue directly. In 2016, researchers at the University of Kentucky applied CBD gel to the skin of rats with arthritis in one knee. Over four days, the treated joints swelled less, immune cells infiltrated the tissue less, and the synovial membrane, the lining inside the joint, thickened less. They measured the swelling with a tape measure and the immune invasion under a microscope, so these were not animals reporting that they felt better. The inflammation itself was smaller.
That is a real anti-inflammatory effect, measured objectively, and it is why the idea deserved human trials.
*A note on the numbers in those studies: they are milligram-per-kilogram doses given to rodents under laboratory conditions, and they do not convert to anything you can buy or take. They appear here as study details, not as guidance.*
Then You Get to People
Here is where the story turns, and where the trial title from the opening comes in.
In that 2021 study, published in the Journal of Crohn’s and Colitis, 56 patients with active Crohn’s disease were randomly assigned to eight weeks of CBD-rich cannabis oil or a matching placebo. Neither the patients nor the investigators knew who got which. The researchers tracked two categories of outcome at once: how patients were doing, and how the disease was doing.
If you were one of the 30 patients assigned to the cannabis oil, you noticed. The Crohn’s Disease Activity Index, a standard symptom score, dropped from 282 to 166 while the placebo group barely moved. Quality of life climbed from 74 to 91 against 75. Both differences were statistically significant.
The disease results were flat. The endoscopic score, which comes from an actual camera looking at actual intestine, showed no meaningful difference between the groups. The p-value was 0.75. In plain terms, a change that small is entirely consistent with chance. C-reactive protein and calprotectin, the two markers used to track inflammatory activity, in the authors’ own words, “remained unchanged.”
The research team drew the conservative conclusion. Eight weeks of CBD-rich cannabis produced significant clinical and quality-of-life improvement, they wrote, without significant changes in inflammatory parameters or endoscopic scores. Then they added a line most coverage of the study leaves out: until further studies are available, cannabis treatment in Crohn’s disease should be used only in the context of clinical trials.
Those are the people who ran the positive trial, telling you to be careful with their own result.
A second trial found something similar in ulcerative colitis. A 2018 pilot study run across a group of British NHS hospitals randomised patients to ten weeks of CBD-rich botanical extract or placebo. The primary endpoint, the share of patients in remission, was negative: 28 percent on the extract, 26 percent on placebo.
That trial comes with one honest complication. Among the patients who took their capsules as directed, one symptom score did reach significance at P = 0.038. Two things keep that from rescuing the trial. The subset only had to be created because patients tolerated the extract poorly, taking roughly a third fewer capsules than the protocol required, and an analysis assembled after the fact carries far less weight than the endpoint a study was designed around. The trial had also set its significance bar at 10 percent rather than the usual 5, so its own threshold for calling a result real was looser than most.
Does CBD Reduce Inflammation? What Happens When You Pool the Trials
Two trials are still two trials. If you want to know whether a finding holds beyond one research group and one disease, you pool everything anyone has run.
A team at University Medical Centre Utrecht did that for inflammatory bowel disease. They screened 682 records and included 20 studies, 5 randomised and 15 not, then meta-analysed the randomised evidence across 146 participants. Their published conclusion reads like a summary of this entire article:
“Cannabi(noid)s do not induce clinical remission or affect inflammation in IBD patients. However, cannabi(noid)s significantly improve patient-reported symptoms and QoL.”
No effect on inflammatory biomarkers. Clear improvement in abdominal pain, general well-being, nausea, diarrhoea, appetite, and quality of life.
Two findings in that review cut the other way. Patients using cannabis had shorter hospital stays and a lower risk of needing intravenous feeding, and those are hard outcomes rather than feelings. The review does not say which studies produced them. The likely source is the observational side, since the five randomised trials ran only eight to ten weeks and were never built to track hospital admissions. On that side patients chose cannabis for themselves, so healthier patients choosing it would produce the same numbers. Worth knowing. Not worth leaning on.
So, does CBD reduce inflammation? In a dish and in animals, reliably. In people with inflammatory disease, in the randomised trials run so far, no measurable effect on the inflammation, alongside a real and repeatable effect on how those people feel.
Both halves of that sentence are true.
CBD for Inflammation and Pain Are Two Different Questions
When people search for CBD for inflammation and pain, they almost always mean one thing: they hurt, and somebody told them inflammation is the reason. Split those two into separate questions and the evidence starts saying something different.
We have written before about how cannabis affects pain in the brain, and the short version is that it tends to change your relationship to pain rather than switch the pain off. That mechanism sits in the nervous system. It has little to do with whether your joint is inflamed.
Which brings us to a trial that deserves more attention than it gets. In 2022, rheumatologists at Aalborg University Hospital in Denmark ran the study closest to what patients actually do. They enrolled 136 patients with hand osteoarthritis or psoriatic arthritis, an inflammatory arthritis that develops in some people with psoriasis. All of them still had moderate pain despite existing treatment. Each received either synthetic CBD, at a daily amount inside the range sold over the counter, or a placebo. Twelve weeks, double-blind, published in Pain.
The difference in pain between the CBD group and the placebo group was 0.23 millimetres on a 100-millimetre scale. The p-value was 0.96. In practical terms, nothing happened. Twenty-two percent of the CBD patients had a meaningful pain reduction, and so did 21 percent of the placebo patients. Sleep, anxiety, and depression scores showed no significant effect either.
The amounts used in that trial were chosen by the researchers for a controlled study and are reported here only to describe what was tested. Nothing in this article is a dosing recommendation.
That result is not proof that CBD never helps anyone. It is strong evidence that pure CBD, at the amounts most people buy, in patients with genuinely inflammatory arthritis, did not beat a placebo over three months. Any honest account of CBD for arthritis has to sit with that.
What the Trials Show for Cannabis and Rheumatoid Arthritis
Before the reviews had piled up enough negative findings to settle the question, one small study produced the result everyone in this field was hoping for.
In 2006, at the Royal National Hospital for Rheumatic Diseases in Bath, 58 patients with rheumatoid arthritis were randomised to five weeks of a mouth spray delivering THC and CBD, or to a placebo. Pain on movement improved. Pain at rest improved. Sleep quality improved. And DAS28, a composite measure of disease activity, was significantly suppressed.
That is the strongest published result in cannabis and rheumatoid arthritis, and it comes with three caveats the authors themselves supplied. Fifty-eight patients is small. Five weeks is short. And in their words, “the differences are small and variable across the population.”
One more caveat is worth adding, because it goes to the theme of this article. DAS28 is a composite score built from tender and swollen joint counts, a patient’s own global assessment, and an inflammatory marker. Moving it is a real finding. It is not the same as showing that inflammation itself measurably fell.
Twenty years later, that trial has not been repeated at scale. When a group of rheumatologists systematically reviewed every randomised trial of cannabinoids for pain in rheumatic disease, they found four studies in total, covering fibromyalgia, spinal pain, and that single RA trial. Not one trial in osteoarthritis patients existed. Three of the four carried a high risk of bias. Their conclusion: insufficient evidence to recommend any cannabinoid preparation for symptom management in these conditions.
Four small trials. That is the whole shelf.
What About Anti-Inflammatory Cannabis and THC?
The shelf for rheumatoid arthritis is thin. THC has its own shelf, and it is not much fuller.
Most searches for anti inflammatory cannabis or thc for inflammation assume the two compounds behave alike. They do not. But the human trials of THC end up in the same place the CBD trials did, by a different road.
The best-known study is a 2013 trial of 21 patients with Crohn’s disease severe enough that steroids, immunomodulators, and anti-TNF drugs had all failed them. They received either THC-rich cannabis or placebo cigarettes made from cannabis flowers with the THC removed. Ninety percent of the treated patients had a clinical response against 40 percent on placebo, and three came off steroid dependency.
That sounds decisive until you read the endpoint. The study was designed to test whether cannabis could induce remission, and on that measure, its primary one, the result was not statistically significant. The authors said so in their conclusion. Twenty-one patients is a small trial, and the difference in remission rates could easily have been chance.
That study used a specific measured quantity of THC in a controlled setting. It is described here as a study detail. It is not a recommendation, and no amount stated in any research paper should be treated as a target.
So THC has the same signature as CBD in this space: patients report feeling better, and the objective disease measures decline to cooperate.
The Part Physicians Take Seriously
Everything above is scorekeeping. This section is why the score matters.
Rheumatoid arthritis erodes joints. Crohn’s disease scars bowel. Both do that damage whether or not you can feel it on a given Tuesday. Disease-modifying drugs and biologics, the class of medications aimed at specific parts of the immune response, exist because slowing that damage is a separate job from making a patient comfortable, and it is the job that determines what someone’s hands or intestines look like in fifteen years.
Put the evidence together and the risk becomes obvious. Symptom relief with no effect on inflammation can make you feel like your disease is under control at a moment when it is not. If that feeling leads someone to stretch out their biologic, skip a rheumatology appointment, or quietly stop a working medication, the damage continues on schedule with nobody watching.
We are not telling you cannabis is dangerous for inflammatory disease. Nothing in the trials above suggests that. We are telling you that symptom relief and disease control are different achievements, and that treating one as evidence of the other is the specific mistake costing patients function.
Someone needs to be watching your actual markers while you experiment with how you feel.
Talk to a physician who reads your markers, not just your symptoms
Why We Will Not Tell You Which Product to Buy
Every week, someone asks us which strain or which ratio works best for inflammation. We decline, and the reason is not caution for its own sake.
If a strain reliably suppressed inflammation in people, it would have shown up somewhere in the trial literature by now, and it has not. Strain names are not standardised between growers. The same name can carry different chemistry from two different shelves. The indica and sativa labels tell you almost nothing about what is in the jar. Pointing at a product would mean inventing an answer the research has not produced.
What a physician can do is different and more useful, and it is the job a medical cannabis evaluation exists to do. They can look at your diagnosis, your current medications, and your lab results, then tell you whether cannabis is reasonable to try alongside the treatment you are already on. More to the point, they can tell you what to keep watching. Feeling better should never become the reason you stop measuring.
Get a physician’s read on whether cannabis fits your current treatment plan
Where This Leaves You
If you came here trying to sort what the CBD marketing claims from what the trials measured, the plain summary is short.
CBD is a genuine anti-inflammatory in cells and in animals, with well-replicated effects and a sensible mechanism. In human trials of inflammatory disease, it has repeatedly improved how patients feel without measurably changing the inflammation underneath. For pain in inflammatory arthritis, the largest and most relevant trial found no difference from placebo at all. The strongest published result in rheumatoid arthritis is a 58-patient trial from 2006. Nobody has repeated it.
Feeling better is worth something. If you live with chronic inflammatory disease, less pain and better sleep are not a consolation prize, and the trials measuring quality of life measured something real.
Do not mistake it for the disease backing down. Those are different things, and the research has been unusually clear about which one it found.
Common Questions
Does CBD reduce inflammation?
In laboratory cells and in animal models, yes, and consistently. In human trials of inflammatory bowel disease, pooled results showed no effect on inflammatory biomarkers, though patient-reported symptoms and quality of life improved significantly.
Is CBD good for inflammation and pain?
The evidence separates them. For pain in hand osteoarthritis and psoriatic arthritis, a 136-patient randomised trial found no difference between CBD and placebo over 12 weeks. For symptoms in inflammatory bowel disease, patients report real improvement even when their markers do not change.
Can CBD replace my arthritis medication?
This is a question for the physician managing your condition, and the honest evidence points toward no. Disease-modifying treatments are prescribed to slow tissue damage, a goal cannabinoids have not met in human trials.
Is THC anti-inflammatory?
The laboratory evidence suggests cannabinoids act on immune receptors, but human trials of THC-rich cannabis in Crohn’s disease improved symptoms without meeting their remission endpoints. The pattern matches what has been found with CBD.
What is the best strain for inflammation?
We do not recommend strains, and no research supports a specific one. Strain names vary between growers and predict a product’s chemistry poorly. The compounds and amounts matter more, and both belong in a conversation with a physician.
Does an inflammatory condition qualify for a medical cannabis certification?
It depends on your state. Many programs list conditions such as rheumatoid arthritis, Crohn’s disease, or chronic pain, though the wording varies from program to program. The evaluation is conducted by a licensed physician and tells you what applies where you live.
See whether your condition qualifies in your state
This article is for educational purposes and is not medical advice. It does not diagnose, treat, or replace care from a licensed clinician. Cannabis affects each person differently. Never stop or change a prescribed treatment without speaking to the physician managing your condition.
Sources
1. Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial. Journal of Crohn’s and Colitis, 2021;15(11):1799-1806. PMID 33858011.
2. Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH. A Systematic Review With Meta-Analysis of the Efficacy of Cannabis and Cannabinoids for Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021;55(9):798-809. PMID 32675631.
3. Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain, 2022;163(6):1206-1214. PMID 34510141.
4. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford), 2006;45(1):50-52. PMID 16282192.
5. Fitzcharles MA, Baerwald C, Ablin J, Häuser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases: A systematic review of randomized controlled trials. Schmerz, 2016;30(1):47-61. PMID 26767993.
6. Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 2013;11(10):1276-1280. PMID 23648372.
7. Irving PM, Iqbal T, Nwokolo C, et al. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis. Inflammatory Bowel Diseases, 2018;24(4):714-724. PMID 29538683.
8. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences, 2000;97(17):9561-9566. PMID 10920191.
9. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 2016;20(6):936-948. PMID 26517407.
10. Stowe EW, White DK, Boring MA, Barbour KE, Lites TD, Fallon EA. Prevalence of Arthritis-Attributable Activity Limitations, United States, 2023. Arthritis Care & Research, 2026;78(8):967-973. PMID 41399096.
11. National Center for Complementary and Integrative Health. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
12. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis. https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
